P.E.T.Net pharmaceuticals licenses technology
Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use
Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use the technology to develop its own diagnostic tests, as well as to participate in research partnerships with pharmaceutical companies. The tests being developed will utilize positron-emitting molecular probes specific to the plaques and neural tangles associated with Alzheimer’s disease.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
